Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05570149
EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
Sponsor: IRCCS San Raffaele Roma
View on ClinicalTrials.gov
Summary
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Official title: EptinezuMaB in ReAl-world evidenCE: a 12-Months, Multicenter, Real-Life, Cohort Study in High-Frequency Episodic and Chronic Migraine (the EMBRACE Study)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2023-01-01
Completion Date
2026-12-31
Last Updated
2025-05-01
Healthy Volunteers
No
Conditions
Interventions
DRUG
Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution
migraine prophylaxis
Locations (1)
IRCCS San Raffaele Roma
Roma, RM, Italy